About ATP synthase mitochondrial F1 complex assembly factor 1
ATP synthase mitochondrial F1 complex assembly factor 1 (ATPAF1) is a protein
from Homo sapiens identified by UniProt accession
Q5TC12, 328 residues long.
MolForge cross-references it against 0 known binders and
15 disease associations.
Target properties
| Protein name | ATP synthase mitochondrial F1 complex assembly factor 1 |
|---|
| UniProt accession | Q5TC12 |
|---|
| Gene | ATPAF1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 328 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (15)
Diseases linked to this target (Open Targets).
- Alzheimer disease · score 0.29
- lysosomal storage disease · score 0.29
- neurodegenerative disease · score 0.29
- multiple sclerosis · score 0.29
- Parkinson disease · score 0.29
- nonpapillary renal cell carcinoma · score 0.04
- synophrys measurement · score 0.02
- neoplasm · score 0.01
- Abnormal sperm morphology · score 0.01
- Cognitive impairment · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5TC12-F1 | alphafold | PREDICTED | 74.64 | — |
Amino-acid sequence (328 residues)
MAAVVVAAAG GAGPAVLQVA GLYRGLCAVR SRALGLGLVS PAQLRVFPVR PGSGRPEGGA DSSGVGAEAE LQANPFYDRY RDKIQLLRRS DPAAFESRLE KRSEFRKQPV GHSRQGDFIK CVEQKTDALG KQSVNRGFTK DKTLSSIFNI EMVKEKTAEE IKQIWQQYFA AKDTVYAVIP AEKFDLIWNR AQSCPTFLCA LPRREGYEFF VGQWTGTELH FTALINIQTR GEAAASQLIL YHYPELKEEK GIVLMTAEMD STFLNVAEAQ CIANQVQLFY ATDRKETYGL VETFNLRPNE FKYMSVIAEL EQSGLGAELK CAQNQNKT
Explore ATP synthase mitochondrial F1 complex assembly factor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets